<DOC>
	<DOCNO>NCT01345240</DOCNO>
	<brief_summary>This study design support indication candidate vaccine ( also refer GSK 257049 RTS , S record ) hepatitis B virus infection , administer primary vaccination integrate Expanded Program Immunization ( EPI ) regimen infant live sub-Saharan Africa .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Hepatitis B Antigen GSK Biologicals ' Candidate Malaria Vaccine ( 257049 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : A male female infant age 8 12 week inclusive time first vaccination Signed thumbprinted informed consent obtain parent ( ) /Legally Acceptable Representative [ LAR ( ) ] child . Where parent ( ) /LAR ( ) illiterate , consent form countersign independent witness Subjects investigator believe parent ( ) /LAR ( ) comply requirement protocol Healthy subject establish medical history clinical examination enter study Born mother Hepatitis B surface antigen ( HBsAg ) negative Born mother Human Immunodeficiency Virus ( HIV ) negative Born normal gestation period 36 42 week inclusive . The following criterion check time study entry . If ANY exclusion criterion applies , subject must include study : Child care Acute disease and/or fever time enrolment Serious acute chronic illness determine clinical physical examination laboratory screen test Laboratory screen test range Previous vaccination diphtheria , tetanus , pertussis , Haemophilus influenzae type b , Streptococcus pneumoniae , hepatitis B vaccine rotavirus vaccine . Planned administration/administration license vaccine foreseen study protocol within 7 day first dose study vaccine . Use drug vaccine approve indication study vaccine within 30 day precede first dose study vaccine , plan use study period . Administration immunoglobulins and/or blood product period birth Dose 1 within three month precede plan vaccine administration study period . Chronic administration immunosuppressant immunemodifying drug period birth Dose 1 . Concurrently participate another clinical study time study period , subject expose investigational noninvestigational product . Same sex twin Maternal death History allergic reaction anaphylaxis previous immunization . History allergic disease reaction likely exacerbate component vaccine . Any finding investigator feel would increase risk adverse outcome participation trial . Any finding investigator feel would result data collect incomplete poor quality . Previous participation malaria vaccine trial .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Africa</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Malaria vaccine</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>EPI</keyword>
</DOC>